rs139633545
Positions:
Variant summary
Our verdict is Likely benign. Variant got -5 ACMG points: 0P and 5B. BP6BS2
The NM_002294.3(LAMP2):āc.1142T>Cā(p.Val381Ala) variant causes a missense change involving the alteration of a conserved nucleotide. The variant allele was found at a frequency of 0.0000546 in 1,209,735 control chromosomes in the GnomAD database, including 1 homozygotes. There are 21 hemizygotes in GnomAD. Variant has been reported in ClinVar as Conflicting classifications of pathogenicity (no stars).
Frequency
Genomes: š 0.00023 ( 0 hom., 7 hem., cov: 23)
Exomes š: 0.000036 ( 1 hom. 14 hem. )
Consequence
LAMP2
NM_002294.3 missense
NM_002294.3 missense
Scores
7
8
2
Clinical Significance
Conservation
PhyloP100: 8.51
Genes affected
LAMP2 (HGNC:6501): (lysosomal associated membrane protein 2) The protein encoded by this gene is a member of a family of membrane glycoproteins. This glycoprotein provides selectins with carbohydrate ligands. It may play a role in tumor cell metastasis. It may also function in the protection, maintenance, and adhesion of the lysosome. Alternative splicing of this gene results in multiple transcript variants encoding distinct proteins. [provided by RefSeq, Jul 2008]
Genome browser will be placed here
ACMG classification
Classification made for transcript
Verdict is Likely_benign. Variant got -5 ACMG points.
BP6
Variant X-120431414-A-G is Benign according to our data. Variant chrX-120431414-A-G is described in ClinVar as [Conflicting_classifications_of_pathogenicity]. Clinvar id is 180882.We mark this variant Likely_benign, oryginal submissions are: {Likely_benign=1, Benign=2, Uncertain_significance=2}. Variant chrX-120431414-A-G is described in Lovd as [Benign]. Variant chrX-120431414-A-G is described in Lovd as [Likely_benign].
BS2
High Hemizygotes in GnomAd4 at 7 XL gene
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
LAMP2 | NM_002294.3 | c.1142T>C | p.Val381Ala | missense_variant | 9/9 | ENST00000200639.9 | NP_002285.1 | |
LAMP2 | NM_001122606.1 | c.1094-2788T>C | intron_variant | NP_001116078.1 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
LAMP2 | ENST00000200639.9 | c.1142T>C | p.Val381Ala | missense_variant | 9/9 | 1 | NM_002294.3 | ENSP00000200639 | P3 | |
LAMP2 | ENST00000434600.6 | c.1094-2788T>C | intron_variant | 1 | ENSP00000408411 | A1 | ||||
LAMP2 | ENST00000706600.1 | c.*1001T>C | 3_prime_UTR_variant | 9/9 | ENSP00000516464 | |||||
LAMP2 | ENST00000486593.5 | c.*127T>C | 3_prime_UTR_variant, NMD_transcript_variant | 7/7 | 5 | ENSP00000431526 |
Frequencies
GnomAD3 genomes AF: 0.000232 AC: 26AN: 112272Hom.: 0 Cov.: 23 AF XY: 0.000203 AC XY: 7AN XY: 34446
GnomAD3 genomes
AF:
AC:
26
AN:
112272
Hom.:
Cov.:
23
AF XY:
AC XY:
7
AN XY:
34446
Gnomad AFR
AF:
Gnomad AMI
AF:
Gnomad AMR
AF:
Gnomad ASJ
AF:
Gnomad EAS
AF:
Gnomad SAS
AF:
Gnomad FIN
AF:
Gnomad MID
AF:
Gnomad NFE
AF:
Gnomad OTH
AF:
GnomAD3 exomes AF: 0.000116 AC: 21AN: 181255Hom.: 0 AF XY: 0.000119 AC XY: 8AN XY: 67135
GnomAD3 exomes
AF:
AC:
21
AN:
181255
Hom.:
AF XY:
AC XY:
8
AN XY:
67135
Gnomad AFR exome
AF:
Gnomad AMR exome
AF:
Gnomad ASJ exome
AF:
Gnomad EAS exome
AF:
Gnomad SAS exome
AF:
Gnomad FIN exome
AF:
Gnomad NFE exome
AF:
Gnomad OTH exome
AF:
GnomAD4 exome AF: 0.0000364 AC: 40AN: 1097463Hom.: 1 Cov.: 29 AF XY: 0.0000386 AC XY: 14AN XY: 362985
GnomAD4 exome
AF:
AC:
40
AN:
1097463
Hom.:
Cov.:
29
AF XY:
AC XY:
14
AN XY:
362985
Gnomad4 AFR exome
AF:
Gnomad4 AMR exome
AF:
Gnomad4 ASJ exome
AF:
Gnomad4 EAS exome
AF:
Gnomad4 SAS exome
AF:
Gnomad4 FIN exome
AF:
Gnomad4 NFE exome
AF:
Gnomad4 OTH exome
AF:
GnomAD4 genome AF: 0.000232 AC: 26AN: 112272Hom.: 0 Cov.: 23 AF XY: 0.000203 AC XY: 7AN XY: 34446
GnomAD4 genome
AF:
AC:
26
AN:
112272
Hom.:
Cov.:
23
AF XY:
AC XY:
7
AN XY:
34446
Gnomad4 AFR
AF:
Gnomad4 AMR
AF:
Gnomad4 ASJ
AF:
Gnomad4 EAS
AF:
Gnomad4 SAS
AF:
Gnomad4 FIN
AF:
Gnomad4 NFE
AF:
Gnomad4 OTH
AF:
Alfa
AF:
Hom.:
Bravo
AF:
ESP6500AA
AF:
AC:
6
ESP6500EA
AF:
AC:
0
ExAC
AF:
AC:
20
ClinVar
Significance: Conflicting classifications of pathogenicity
Submissions summary: Uncertain:2Benign:4
Revision: criteria provided, conflicting classifications
LINK: link
Submissions by phenotype
not specified Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Laboratory for Molecular Medicine, Mass General Brigham Personalized Medicine | Mar 23, 2015 | Variant classified as Uncertain Significance - Favor Benign. The p.Val381Ala var iant in LAMP2 has not been previously reported in individuals with cardiomyopath y or Danon disease, but has been identified in 0.1% (11/8513) African chromosome s, including 3 hemizygotes, by the Exome Aggregation Consortium (ExAC, http://ex ac.broadinstitute.org; dbSNP rs139633545). Computational prediction tools and co nservation analysis suggest that this variant may impact the protein, though thi s information is not predictive enough to determine pathogenicity. In summary, w hile the clinical significance of the p.Val381Ala variant is uncertain, its freq uency and presence in multiple hemizygous control individuals suggests that it is more likely to be benign. - |
Cardiomyopathy Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | CHEO Genetics Diagnostic Laboratory, Children's Hospital of Eastern Ontario | May 11, 2021 | - - |
Danon disease Benign:1
Benign, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Jan 11, 2024 | - - |
LAMP2-related disorder Benign:1
Likely benign, no assertion criteria provided | clinical testing | PreventionGenetics, part of Exact Sciences | Nov 17, 2020 | This variant is classified as likely benign based on ACMG/AMP sequence variant interpretation guidelines (Richards et al. 2015 PMID: 25741868, with internal and published modifications). - |
not provided Benign:1
Benign, criteria provided, single submitter | clinical testing | GeneDx | Oct 02, 2020 | - - |
Cardiovascular phenotype Benign:1
Likely benign, criteria provided, single submitter | clinical testing | Ambry Genetics | Jul 18, 2019 | This alteration is classified as likely benign based on a combination of the following: seen in unaffected individuals, population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity. - |
Computational scores
Source:
Name
Calibrated prediction
Score
Prediction
AlphaMissense
Uncertain
CardioboostCm
Benign
BayesDel_addAF
Uncertain
D
BayesDel_noAF
Pathogenic
CADD
Pathogenic
DANN
Uncertain
DEOGEN2
Uncertain
T
FATHMM_MKL
Pathogenic
D
LIST_S2
Uncertain
D
M_CAP
Pathogenic
D
MetaRNN
Uncertain
D
MetaSVM
Uncertain
T
MutationAssessor
Pathogenic
M
MutationTaster
Benign
D;D;D
PROVEAN
Uncertain
D
REVEL
Pathogenic
Sift
Pathogenic
D
Sift4G
Pathogenic
D
Polyphen
D
Vest4
MVP
ClinPred
T
GERP RS
RBP_binding_hub_radar
RBP_regulation_power_radar
Varity_R
Splicing
Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
Details are displayed if max score is > 0.2
Find out detailed SpliceAI scores and Pangolin per-transcript scores at